LYELL IMMUNOPHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.33 USD | +7.37% |
|
+1.30% | +20.10% |
| 03-04 | North American Morning Briefing : Stock Futures -2- | DJ |
| 02-28 | Lyell Immunopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Chart calendar Lyell Immunopharma, Inc.
3d81161b5b113ff36fbf.M-RDfVsB0W4qZ6lsMiGofWIdUj6lwcZRCzQhprOUpr0.db4tERRVnx8bM8ZVYWrdERYqCGTtqOsJUnpli_bZ3tRssRkIaVSZBlMGmQ~2d1beaf21b8e72bdb6f608c6d3d572d0
Upcoming events on Lyell Immunopharma, Inc.
Past events on Lyell Immunopharma, Inc.
| 09/04/2024 22:30 | American Association for Cancer Research Meeting - Abstract Number: 6593 |
| 09/04/2024 17:00 | American Association for Cancer Research Meeting - Abstract Number: 4067 |
| 07/04/2024 21:30 | American Association for Cancer Research Meeting - Abstract Number: 49 |
| 26/03/2024 19:30 | H.C. Wainwright Cell Therapy Virtual Conference |
| 04/03/2024 16:10 | TD Cowen Health Care Conference |
| 28/02/2024 21:05 | Q4 2023 Earnings Release |
| 10/01/2024 16:15 | JPMorgan Healthcare Conference |
| 07/11/2023 21:05 | Q3 2023 Earnings Release |
| 04/11/2023 18:55 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 754 |
| 04/11/2023 18:55 | Society for Immunotherapy of Cancer Meeting - Abstract No.: 278 |
| 03/11/2023 19:00 | Society for Immunotherapy of Cancer Meeting - Abstract No.: 393 |
| 03/11/2023 19:00 | Society for Immunotherapy of Cancer Meeting - Abstract No.: 1047 |
| 03/11/2023 19:00 | Society for Immunotherapy of Cancer Meeting - Abstract No.: 747 |
| 03/11/2023 19:00 | Society for Immunotherapy of Cancer Meeting - Abstract Number: 379 |
| 27/09/2023 20:35 | Cantor Global Healthcare Conference |
| 12/09/2023 14:00 | H.C. Wainwright Global Investment Conference |
| 11/09/2023 21:55 | Morgan Stanley Global Healthcare Conference |
| 08/08/2023 21:05 | Q2 2023 Earnings Release |
| 16/06/2023 16:30 | Annual General Meeting |
| 14/06/2023 22:00 | Goldman Sachs Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 | 10,7 9,69 9.92% | 84,7 43,7 93.91% | 0,13 0,12 5.48% | 2,00 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 | -201 -228 11.72% | -169 -203 16.85% | -227 -220 -3.06% | -227 |
|
EBIT Million USD | Released Forecast Spread | 0,00 | -215 -237 9.52% | -187 -224 16.64% | -247 -250 1.11% | -239 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | 0,00 | 0,00 0,00 - | -183 -242 24.28% | -235 -240 2.14% | -225 |
|
Net income Million USD | Released Forecast Spread | -204 | -250 -238 -5.01% | -183 -243 24.67% | -235 -240 2.14% | -225 |
|
EPS USD | Released Forecast Spread | 0,00 | -1,84 -1,43 -28.88% | -0,74 -0,98 24.59% | -0,93 -0,96 2.83% | -0,87 |
| Announcement Date | 12/05/21 | 29/03/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 2,82 2,85 -0.98% | 0,55 1,50 -63.13% | 35,7 1,60 2133.81% | 0,00 2,70 -99.89% | 48,4 2,80 1628.07% | 0,07 0,00 - | 0,03 0,00 - | 0,03 0,00 - | 0,01 0,00 - | 0,00 | 0,00 | 0,00 | 0,00 |
|
EBITDA Million USD | Released Forecast Spread | -60,8 -61,4 0.93% | -53,9 -51,7 -4.31% | -54,5 -53,6 -1.57% | ||||||||||
|
EBIT Million USD | Released Forecast Spread | -47,5 -65,7 27.59% | -68,6 -69,7 1.64% | -37,3 -69,7 46.5% | -66,4 -75,5 11.99% | -14,8 -76,7 80.72% | -62,6 -71,6 12.64% | -65,9 -72,0 8.51% | -59,0 -68,3 13.56% | -59,5 -62,7 5.12% | -59,4 | -61,1 | -59,6 | -62,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -68,1 -63,0 -8.17% | -36,3 -66,0 44.97% | -70,3 -56,8 -23.59% | -8,40 -60,1 86.03% | -67,0 -64,6 -3.64% | -63,9 -59,8 -6.8% | -50,9 -63,1 19.39% | -52,9 -49,8 -6.37% | -50,6 | -51,9 | -52,3 | -53,2 | |
|
Net income Million USD | Released Forecast Spread | -83,7 -72,0 -16.26% | -68,1 -72,3 5.72% | -36,3 -66,0 44.97% | -70,3 -75,6 7.09% | -8,40 -74,4 88.71% | -67,0 -71,2 6.02% | -63,9 -70,7 9.59% | -50,9 -66,6 23.66% | -52,9 -60,2 12.01% | -50,6 | -51,9 | -52,3 | -53,2 |
|
EPS USD | Released Forecast Spread | -0,18 -0,28 34.65% | -0,28 -0,29 1.87% | -0,15 -0,28 47.13% | -0,28 -0,31 8.6% | -0,03 -0,24 87.55% | -0,27 -0,28 4.7% | -0,26 -0,27 4.88% | -0,20 -0,25 21.41% | -0,20 -0,23 12.51% | -0,21 | -0,22 | -0,22 | -0,22 |
| Announcement Date | 29/03/22 | 10/05/22 | 04/08/22 | 08/11/22 | 28/02/23 | 04/05/23 | 08/08/23 | 07/11/23 | 28/02/24 | - | - | - | - |
More events
Past sector events for Lyell Immunopharma, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- LYEL Stock
- Calendar Lyell Immunopharma, Inc.
